Table 2 Summary of Types of Information Used for 50 Additional Sample Patients to Test Simple Rules-Based Tool

Patient Characteristics

Age, gender, body mass index, exercise level, race/ethnicity, sexual activity

Cardiovascular Risk Factors

Hypertension, dyslipidemia, diabetes, smoking, obesity

Quantitative Markers

Vital capacity, ejection fraction, left ventricular ejection fraction, coronary artery calcium score, QRS duration, QT interval, B-type natriuretic peptide, erythrocyte sedimentation rate, total cholesterol, high density lipoprotein cholesterol, low density lipoprotein cholesterol, fasting triglycerides, hemoglobin A1C, glucose, systolic blood pressure, diastolic blood pressure, baseline strain measurements, troponin, atherosclerotic cardiovascular disease score, albumin, albuminuria, ankle-brachial index

Clinical Markers

Angina, left ventricular diastolic dysfunction, new murmur, acute pericarditis, cardiac tamponade

Medical History

Pre-existing cardiovascular disease, heart failure, coronary artery disease, myocardial infarction, valvular heart disease, cancer therapy-related cardiac dysfunction, stroke or transient ischemic attack, venous thromboembolism, Raynaud’s, cerebrovascular disease, thromboembolic disease, cardiomyopathy, arrhythmia, cardiothoracic surgery, atherosclerosis, retinopathy, neuropathy, pregnancy-associated disorders, human immunodeficiency virus, liver disease, systolic anterior motion

Family History

Early cardiovascular disease, hypercholesterolemia, premature coronary artery disease

Cancer Type

Mediastinal tumors, cardiac metastasis, primary tumors of the heart

Imaging

Echocardiography, 2-dimensional echocardiography, 3-dimensional echocardiography, study quality

Timing

Evaluation before, during, or after cancer treatment (> 6 months and < 12 months)

Medications

Metformin, lipid-lowering therapy (Proprotein convertase subtilisin/kexin type 9 inhibitors, statin therapy, fenofibrate), chemotherapy (high/low dose epirubicin, high/low dose doxorubicin, trastuzumab, 5-Fluorouracil/capecitabine, paclitaxel, vascular endothelial growth factor inhibitors, erlotinib, nilotinib, ponatinib, thalidomide, lenalidomide), sequential or combination therapy

Radiation

Location (anterior or left chest, chest, head/neck, abdomen/pelvis), dose (> 2 Gy/day, ≥ 35 Gy, > 30 Gy), lack of shielding during radiation therapy